Cargando…

High LDL cholesterol and statin use were independently associated with lower eight-year mortality in a cohort free from terminal illness, cardiovascular disease, and diabetes at baseline

Detalles Bibliográficos
Autor principal:	Thulesius, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Informa Healthcare 2014
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137895/ https://www.ncbi.nlm.nih.gov/pubmed/24533848 http://dx.doi.org/10.3109/02813432.2014.869410

Ejemplares similares

Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?
por: Khan, Safi U., et al.
Publicado: (2020)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
por: Storey, Benjamin C., et al.
Publicado: (2018)

Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta‐Analysis
por: Zhang, Xin‐Lin, et al.
Publicado: (2019)

Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events
por: Sakuma, Masashi, et al.
Publicado: (2022)

Pre-Treatment with Statins for Coronary Intervention: Pleiotropy of Statins or Effect of LDL-cholesterol Reduction?
por: Habon, Tamas, et al.
Publicado: (2016)

Beyond LDL-Cholesterol: The Role of Low HDL-Cholesterol and Elevated TG in Residual Cardiovascular Risk Remaining After Statin Therapy
por: Watson, Karol E.
Publicado: (2008)

Prediction of LDL cholesterol response to statin using transcriptomic and genetic variation
por: Kim, Kyungpil, et al.
Publicado: (2014)

Individualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C?
por: Clem, James R, et al.
Publicado: (2009)

Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol
por: Nichols, Gregory A., et al.
Publicado: (2018)

Lipid-lowering therapies and achievement of LDL-cholesterol targets
por: Rizzo, Manfredi, et al.
Publicado: (2012)

Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins
por: Leatherman, Sarah, et al.
Publicado: (2022)

Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins
por: Postmus, Iris, et al.
Publicado: (2014)

Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
por: Krähenbühl, Stephan, et al.
Publicado: (2016)

Racial Differences in the Cholesterol-Lowering Effect of Statin
por: Naito, Ryo, et al.
Publicado: (2017)

New and emerging lipid-modifying drugs to lower LDL cholesterol
por: Kosmas, Constantine E, et al.
Publicado: (2021)

The Expected Cardiovascular Benefit of Plasma Cholesterol Lowering with or Without LDL-C Targets in Healthy Individuals at Higher Cardiovascular Risk
por: Cesena, Fernando Henpin Yue, et al.
Publicado: (2017)

Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering
por: Bandyopadhyay, Dhrubajyoti, et al.
Publicado: (2018)

Statin Intensity or Achieved LDL? Practice-based Evidence for the Evaluation of New Cholesterol Treatment Guidelines
por: Ross, Elsie Gyang, et al.
Publicado: (2016)

Should We Intensify Statin Management in ACS Patients with Very Low LDL Cholesterol Levels?
por: Han, Ki Hoon
Publicado: (2019)

Intensity of Statin Treatment in Korean Patients with Acute Myocardial Infarction and Very Low LDL Cholesterol
por: Sim, Doo Sun, et al.
Publicado: (2019)

An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System
por: Lucas, Joseph E., et al.
Publicado: (2017)

Statins redux: A re-assessment of how statins lower plasma cholesterol
por: Raghow, Rajendra
Publicado: (2017)

Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME(®)
por: Langslet, Gisle, et al.
Publicado: (2020)

LDL cholesterol is associated with higher AD neuropathology burden independent of APOE
por: Wingo, Aliza P, et al.
Publicado: (2022)

When LDL Cholesterol Is Not LDL Cholesterol: LpX, A Clinical Lesson
por: Huygen, Lisa P.M., et al.
Publicado: (2022)

Anti-Inflammatory Effects of Statins Beyond Cholesterol Lowering
por: Joo, Seung-Jae
Publicado: (2012)

RHOA Is a Modulator of the Cholesterol-Lowering Effects of Statin
por: Medina, Marisa W., et al.
Publicado: (2012)

Short-term LDL cholesterol-lowering efficacy of plant stanol esters
por: Hallikainen, Maarit, et al.
Publicado: (2002)

Statin Intensity and Clinical Outcome in Patients with Stable Coronary Artery Disease and Very Low LDL-Cholesterol
por: Lee, Soo Youn, et al.
Publicado: (2016)

Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia
por: Climent, Elisenda, et al.
Publicado: (2017)

Adherence to Statin Therapy and Attainment of LDL Cholesterol Goal Among Patients with Type 2 Diabetes and Dyslipidemia
por: Alwhaibi, Monira, et al.
Publicado: (2019)

Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care
por: Iyen, Barbara, et al.
Publicado: (2021)

Differential influences of LDL cholesterol on functional outcomes after intravenous thrombolysis according to prestroke statin use
por: Kang, You-Ri, et al.
Publicado: (2022)

Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy
Publicado: (2012)

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
por: Cholesterol Treatment Trialists' (CTT) Collaborators
Publicado: (2012)

Lower plasma cholesterol, LDL-cholesterol and LDL-lipoprotein subclasses in adult phenylketonuria (PKU) patients compared to healthy controls: results of NMR metabolomics investigation
por: Cannet, Claire, et al.
Publicado: (2020)

Baseline low-density lipoprotein cholesterol predicts the benefit of adding ezetimibe on statin in statin-naïve acute coronary syndrome
por: Im, Jihaeng, et al.
Publicado: (2021)

Association of LDL-cholesterol subfractions with cardiovascular disorders: a systematic review
por: Chary, Abdolreza, et al.
Publicado: (2023)

The LDL Apolipoprotein B-to-LDL Cholesterol Ratio: Association with Cardiovascular Mortality and a Biomarker of Small, Dense LDLs
por: Silbernagel, Günther, et al.
Publicado: (2022)

LDL-Cholesterol Lowering of Plant Sterols and Stanols—Which Factors Influence Their Efficacy?
por: Trautwein, Elke A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9kanjf4nlvdjm8k66q0dk35l2o